Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Receives $7.35 Consensus PT from Brokerages

Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) have been given an average rating of “Buy” by the seven research firms that are covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in the last year is $7.35.

A number of brokerages recently issued reports on CPRX. Zacks Investment Research cut HENGAN INTL GRP/ADR from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 21st. BidaskClub cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Cantor Fitzgerald reissued a “buy” rating and set a $15.00 price objective on shares of Foamix Pharmaceuticals in a report on Tuesday, May 7th. HC Wainwright set a $25.00 price objective on Onconova Therapeutics and gave the stock a “buy” rating in a report on Tuesday, May 14th. Finally, ValuEngine cut Valero Energy from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th.

In other Catalyst Pharmaceuticals news, CEO Patrick J. Mcenany purchased 25,000 shares of the stock in a transaction on Tuesday, June 11th. The shares were purchased at an average price of $3.23 per share, with a total value of $80,750.00. Following the acquisition, the chief executive officer now directly owns 4,762,693 shares in the company, valued at approximately $15,383,498.39. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 10.70% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Amalgamated Bank purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $28,000. Paloma Partners Management Co purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $30,000. Metropolitan Life Insurance Co. NY raised its holdings in shares of Catalyst Pharmaceuticals by 291.8% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 27,253 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 20,297 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Catalyst Pharmaceuticals by 18.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 36,700 shares of the biopharmaceutical company’s stock valued at $70,000 after acquiring an additional 5,688 shares in the last quarter. Finally, Biltmore Capital Advisors LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at about $79,000. 59.79% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CPRX stock remained flat at $$4.07 on Friday. The stock had a trading volume of 731,600 shares, compared to its average volume of 1,959,629. The company has a quick ratio of 6.07, a current ratio of 6.08 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $418.60 million, a P/E ratio of -12.33 and a beta of 2.60. Catalyst Pharmaceuticals has a 12 month low of $1.85 and a 12 month high of $6.16. The company’s 50 day simple moving average is $3.69.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Monday, May 13th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.12. The firm had revenue of $12.45 million for the quarter, compared to the consensus estimate of $2.40 million. During the same quarter in the previous year, the company posted ($0.06) EPS. As a group, equities analysts forecast that Catalyst Pharmaceuticals will post 0.11 earnings per share for the current year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Featured Story: What is Liquidity?

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.